背景介绍 CD22, also known as Siglec-2, is expressed on the membrane of B-cells. It is reported to act as an inhibitory co-receptor of the B-cell receptor to control the body's B-cell response. In 2017 the FDA approved inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate targeting CD22, for patients with B-cell acute lymphoblastic leukemia (ALL). Additional therapies targeting CD22 are under evaluation. 产品介绍 Recombinant clonal stable CHO cell line constitutively expressing full length human CD22 protein (Genbank #NM_001771) and the firefly luciferase. Surface expression of CD22 was confirmed by flow cytometry.